This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aflalo, E. Articles by Priel, E. Search for Related Content PubMed PubMed Citation Articles by Aflalo, E. Articles by Priel, E.

Inhibition of Topoisomerase I Activity by Tyrphostin Derivatives, Protein Tyrosine Kinase Blockers: Mechanism of Action

Department of Immunology and Microbiology, Faculty of Health Sciences, Cancer Research Center Ben-Gurion University, P.O. Box 653, Beer-Sheva [E. A., S. I., S. S., E. P.], and Department of Organic Chemistry, The Hebrew University, Jerusalem [A. G.], Israel

DNA topoisomerase I (topo I) is a member of a group of essential nuclear enzymes which control and modify the topological state of DNA and is recognized as the target for anticancer drugs. During the course of the catalytic activity of topo I, a covalent bond is formed between a tyrosine group at the active site of the enzyme and a 3' phosphate group along the DNA backbone. This chemical reaction resembles the protein kinase-mediated tyrosine phosphorylation process. We assumed, therefore, that tyrphostins, potent and selective blockers of protein tyrosine kinases, might affect topo I activity. We found that of three derivatives of tyrphostins (AG-555, AG-18, and AG-213) that inhibited topo I activity in an in vitro assay, AG-555 was the most active. Examination of the mechanism by which these compounds act as topo I inhibitors revealed that AG-555 blocked the binding of this enzyme to the DNA due to its interaction with the topo I enzyme. We showed that its mode of action differed from that observed for camptothecin, a known topo I inhibitor. However, AG-555 did not affect the activity of other major DNA binding enzymes (i.e., DNA ligase, DNA polymerase I, and reverse transcriptase). This study suggests that tyrphostins may serve as a new class of topo I inhibitors, and these results also present additional explanations for their antiproliferative effect.

¹ To whom requests for reprints should be addressed.

Received 3/14/94. Accepted 7/28/94.

This article has been cited by other articles:

				N. M. Kogan, M. Schlesinger, E. Priel, R. Rabinowitz, E. Berenshtein, M. Chevion, and R. Mechoulam HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor Mol. Cancer Ther., January 1, 2007; 6(1): 173 - 183. [Abstract] [Full Text] [PDF]

				S. Bendetz-Nezer, A. Gazit, and E. Priel DNA Topoisomerase I As One of the Cellular Targets of Certain Tyrphostin Derivatives Mol. Pharmacol., September 1, 2004; 66(3): 627 - 634. [Abstract] [Full Text] [PDF]